Onradivir

Onradivir
Clinical data
Trade names	Anruiwei; 安睿威
Other names	ZSP-1273
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name (2S,3S)-3-{{#parsoidfragment:2}}6-Cyclopropyl-5-fluoro-2-(5-fluoro-2H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid;
CAS Number	2200336-20-3 ;
PubChem CID	138746841 ;
ChemSpider	115010426 ;
UNII	CZE6G5G466 ;
Chemical and physical data
Formula	C22H22F2N6O2
Molar mass	440.455 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1CC2CCC1[C@@H]([C@H]2NC3=NC(=NC(=C3F)C4CC4)C5=C6C=C(C=NC6=NN5)F)C(=O)O;
	InChI InChI=InChI=1S/C22H22F2N6O2/c23-12-7-13-18(29-30-19(13)25-8-12)21-27-17(11-5-6-11)15(24)20(28-21)26-16-10-3-1-9(2-4-10)14(16)22(31)32/h7-11,14,16H,1-6H2,(H,31,32)(H,25,29,30)(H,26,27,28)/t9?,10?,14-,16-/m0/s1; Key:JCHDJLSIYWBAHI-ZWHBIUKWSA-N;

Last updated December 16, 2025

Onradivir (INN) is an antiviral drug.^[1]^[2] In China it is approved for the treatment of influenza A infections in adults, excluding those at high risk for influenza-related complications.^[3] It acts as an inhibitor of influenza virus polymerase basic protein 2 (PB2),^[3] a crucial subunit of the virus' RNA polymerase complex. It is being developed by Guangdong Raynovent Biotech.^[4]

It is derived from pimodivir and has high chemical similarity to it.^[5]

References

↑ Yang Z, Li Z, Zhan Y, Lin Z, Fang Z, Xu X, et al. (May 2024). "Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial". The Lancet. Infectious Diseases. 24 (5): 535–545. doi:10.1016/S1473-3099(23)00743-0. PMID 38330975.
↑ Yang Z, Zhan Y, Li Z, Lin Z, Fang Z, Li H, et al. (July 2025). "Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial". The Lancet. Respiratory Medicine. 13 (7): 597–610. doi:10.1016/S2213-2600(25)00046-3. PMID 40489986.
1 2 Lee A (December 2025). "Onradivir: First Approval". Drugs. 85 (12): 1609–1612. doi:10.1007/s40265-025-02242-5. PMID 40996478.
↑ "Onradivir - Guangdong Raynovent Biotech". AdisInsight. Springer Nature Switzerland AG.
↑ Yang Y, Rong B, Liu Y, Li H, Liang D, Wen Y, et al. (2025). "Development of an Optimized Synthetic Process for Onradivir Featuring a "One-Pot" Miyaura–Suzuki Coupling Reaction". Organic Process Research & Development. 29 (11): 2674–2684. doi:10.1021/acs.oprd.5c00175.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Yang Z, Li Z, Zhan Y, Lin Z, Fang Z, Xu X, et al. (May 2024). "Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial". The Lancet. Infectious Diseases. 24 (5): 535–545. doi:10.1016/S1473-3099(23)00743-0. PMID 38330975.

[2] Yang Z, Zhan Y, Li Z, Lin Z, Fang Z, Li H, et al. (July 2025). "Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial". The Lancet. Respiratory Medicine. 13 (7): 597–610. doi:10.1016/S2213-2600(25)00046-3. PMID 40489986.

[Lee_2025-3] 1 2 Lee A (December 2025). "Onradivir: First Approval". Drugs. 85 (12): 1609–1612. doi:10.1007/s40265-025-02242-5. PMID 40996478.

[4] "Onradivir - Guangdong Raynovent Biotech". AdisInsight. Springer Nature Switzerland AG.

[5] Yang Y, Rong B, Liu Y, Li H, Liang D, Wen Y, et al. (2025). "Development of an Optimized Synthetic Process for Onradivir Featuring a "One-Pot" Miyaura–Suzuki Coupling Reaction". Organic Process Research & Development. 29 (11): 2674–2684. doi:10.1021/acs.oprd.5c00175.

[1]

[2]

[3]

[4]

[5]